The lack of patient diversity in clinical trial enrolment remains a significant barrier to achieving equitable healthcare outcomes. Underrepresentation has led to non-generalizable clinical knowledge, unequal access to treatment, and persistent health disparities, particularly among minority and disadvantaged groups. Numerous factors contribute to this underrepresentation, spanning from the design of clinical studies to their eventual publication in medical journals. Addressing diversity in clinical trials requires a multifaceted approach, including financial, regulatory, and operational policy changes. These policies must tackle challenges related to recruitment, study design, participant representation, and retention. By linking funding to diversity initiatives, streamlining inclusion criteria, enhancing education, and outreach in underserved communities, and leveraging emerging technologies, clinical trials can become more representative and equitable. This not only improves the scientific validity of trial outcomes but also ensures that medical advancements benefit the broader population, regardless of gender, race, or socio-economic status.